Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CPRX
Strong BuyFull HouseAPPROVECatalyst Pharmaceuticals, Inc. · Healthcare · United States · $3.9B · Avg Vol: $66M/d
Catalyst is a quintessential high-margin compounding story. With an active buyback program and a significant forward-EPS upward revision, the company exhibits both internal momentum and strong capital allocation discipline. Its focused therapeutic area offers the kind of durable pricing power and barrier to entry that aligns with a Terry Smith-style quality mandate.
COMPANY DESCRIPTION
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neurological diseases, with its primary product Firdapse for Lambert-Eaton Myasthenic Syndrome (LEMS). The company holds market exclusivity for its approved rare disease therapy, addressing a significant unmet medical need for a small patient population. It is a niche biopharmaceutical company specializing in treatments for rare neurological disorders.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 214.2M | 398.2M | 491.7M | 589.0M | 40.1% | 597.0M | 636.2M | 717.9M | 10.4% |
| EPS | 0.80 | 0.67 | 1.38 | 1.75 | 29.8% | 1.73 | 2.04 | 2.05 | 8.1% |
| Shares | 105.3M | 107.1M | 120.9M | 122.5M | +16.4% | 122.4M | — | — | — |
| Debt | 3.9M | 3.6M | 3.2M | 2.8M | -10.6% | 2.7M | — | — | — |
| Equity | 300.4M | 387.9M | 727.6M | 954.3M | 47.0% | — | — | — | — |
| Op CF | 116.0M | 143.6M | 239.8M | 208.7M | 21.6% | 208.2M | — | — | — |
| Inv CF | 9.2M | -293.5M | -0.6M | -58.0K | — | — | — | — | — |
| Fin CF | 1.7M | -10.9M | 140.7M | -17.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CPRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CPRX | Catalyst Pharmaceuticals, Inc.(you) | $3.9B | — | Hold |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.3B | 100 | Strong Buy |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.0B | 82 | Strong Buy |
| INVA | Innoviva, Inc. | $1.5B | 93 | Strong Buy |
| EXEL | Exelixis, Inc. | $13.5B | 99 | Strong Buy |
| HALO | Halozyme Therapeutics, Inc. | $12.0B | 95 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $868M | 98 | Strong Buy |
| CRMD | CorMedix Inc. | $647M | 98 | Strong Buy |
| LGND | Ligand Pharmaceuticals Incorporated | $5.6B | 66 | Buy |
| INCY | Incyte Corporation | $25.2B | 96 | Strong Buy |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%